While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...

The treatment for keratosis pilaris is continuous. The condition needs to be maintained. General measures to prevent ...

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy ... locally advanced Merkel cell carcinoma, as ...

The best of them carry the seal of acceptance from ... Incyte announces U.S. FDA Approval of Opzelura (ruxolitinib) cream, a topical JAK inhibitor, for the treatment of atopic dermatitis (AD). Food ...